Share Price and Basic Stock Data
Last Updated: October 17, 2025, 8:45 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Chemo Pharma Laboratories Ltd operates in the pharmaceuticals sector, currently priced at ₹135 with a market capitalization of ₹20.2 Cr. The company has reported no sales across several quarters, spanning from March 2022 to December 2024. This consistent lack of revenue raises concerns about its operational viability and market competitiveness. While the absence of sales might suggest challenges in market penetration or product development, the company has managed to maintain a shareholder base of 6,422 as of March 2025. The absence of reported sales could indicate an over-reliance on other income sources, which have shown variability, including a notable decline of ₹0.38 Cr in June 2022, but a recovery to ₹0.70 Cr by December 2023. This trend underlines the importance of diversifying income streams to mitigate risks associated with a lack of core business revenue.
Profitability and Efficiency Metrics
Chemo Pharma’s profitability metrics reveal a complex picture, with a recorded net profit of ₹0.34 Cr for the most recent reporting period. The company has reported fluctuations in net profit across the quarters, with peaks and troughs primarily influenced by other income. For instance, net profit rose to ₹0.68 Cr in December 2023 after a previous loss of ₹0.15 Cr in March 2023. The return on equity (ROE) stands at 3.47%, while the return on capital employed (ROCE) is at 5.17%. These figures indicate that the company is generating low returns relative to its equity and capital employed, questioning its operational efficiency. Furthermore, the absence of reported operating profits (OPM) across the quarters suggests that controlling expenses remains a challenge, as total expenses reported varied from ₹0.02 Cr to ₹0.18 Cr during the same period, indicating a need for tighter cost management.
Balance Sheet Strength and Financial Ratios
Chemo Pharma’s balance sheet reflects a conservative financial structure, with borrowings recorded at ₹0 Cr, indicating no debt obligations. This positions the company favorably in terms of financial risk, particularly in a capital-intensive industry like pharmaceuticals. The reserves have gradually increased from ₹10 Cr in March 2022 to ₹12 Cr in March 2025, showcasing a modest growth in retained earnings. The price-to-book value (P/BV) ratio is at 0.72x, suggesting that the stock may be undervalued relative to its book value, which could attract long-term investors if operational performance improves. However, the interest coverage ratio remains unreported, raising concerns regarding the company’s ability to manage financial obligations should it incur debt in the future. Overall, while the balance sheet appears solid, the lack of profitability and revenue generation poses significant challenges.
Shareholding Pattern and Investor Confidence
The shareholding structure of Chemo Pharma Laboratories Ltd reflects a diverse ownership model, with promoters holding 27.88% of the equity. Institutional investment is minimal, with domestic institutional investors (DIIs) holding just 0.17% and foreign institutional investors (FIIs) not reported, indicating a lack of confidence from institutional players. The public holds a substantial 71.74% of the shares, which suggests a broad retail investor base. However, the increasing number of shareholders, which rose to 6,422 in March 2025 from 6,226 in September 2022, indicates a growing interest among retail investors, possibly driven by the low stock price. The limited institutional participation raises questions about the company’s growth prospects and overall credibility in the market, which could affect future capital-raising efforts.
Outlook, Risks, and Final Insight
If margins sustain their current trajectory and the company successfully addresses its revenue generation challenges, Chemo Pharma could potentially leverage its strong balance sheet to invest in product development or strategic partnerships. However, the risks are pronounced; the continued lack of sales could lead to operational inefficiencies and further strain on cash flows. Additionally, the absence of institutional backing might limit access to capital markets for future growth. Furthermore, competitive pressures within the pharmaceuticals sector could hinder its recovery if the company fails to innovate or expand its product offerings. In conclusion, while Chemo Pharma Laboratories Ltd has a solid financial foundation, its path to recovery hinges on overcoming significant operational hurdles and regaining investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemo Pharma Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 153 Cr. | 122 | 247/84.3 | 34.9 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,735 Cr. | 435 | 443/192 | 106 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.2 Cr. | 46.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.1 Cr. | 20.6 | 29.1/17.0 | 31.4 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.15 Cr | 1,185.50 | 50.47 | 193.86 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.18 | 0.12 | 0.05 | 0.02 | 0.02 | 0.05 | 0.02 | 0.02 | 0.10 | 0.05 | 0.02 | 0.02 | 0.02 |
| Operating Profit | -0.18 | -0.12 | -0.05 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.10 | -0.05 | -0.02 | -0.02 | -0.02 |
| OPM % | |||||||||||||
| Other Income | 0.13 | -0.38 | 0.59 | 0.19 | -0.10 | 0.43 | 0.46 | 0.70 | 0.25 | 0.30 | 0.63 | -0.15 | -0.16 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.50 | 0.54 | 0.17 | -0.12 | 0.38 | 0.44 | 0.68 | 0.15 | 0.25 | 0.61 | -0.17 | -0.18 |
| Tax % | -400.00% | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% | 0.00% | 0.00% | 293.33% | 0.00% | 0.00% | 0.00% | 88.89% |
| Net Profit | 0.14 | -0.50 | 0.53 | 0.16 | -0.15 | 0.38 | 0.44 | 0.68 | -0.29 | 0.25 | 0.61 | -0.17 | -0.34 |
| EPS in Rs | 0.93 | -3.33 | 3.53 | 1.07 | -1.00 | 2.53 | 2.93 | 4.53 | -1.93 | 1.67 | 4.07 | -1.13 | -2.27 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemo Pharma Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Expenses, as of Mar 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.02 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.02 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded -0.02 Cr..
- For OPM %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Other Income, as of Mar 2025, the value is -0.16 Cr.. The value appears to be declining and may need further review. It has decreased from -0.15 Cr. (Dec 2024) to -0.16 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.18 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Dec 2024) to -0.18 Cr., marking a decrease of 0.01 Cr..
- For Tax %, as of Mar 2025, the value is 88.89%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 88.89%, marking an increase of 88.89%.
- For Net Profit, as of Mar 2025, the value is -0.34 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Dec 2024) to -0.34 Cr., marking a decrease of 0.17 Cr..
- For EPS in Rs, as of Mar 2025, the value is -2.27. The value appears to be declining and may need further review. It has decreased from -1.13 (Dec 2024) to -2.27, marking a decrease of 1.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -12 |
| OPM % | |||||||||||||
| Other Income | 0 | 0 | 0 | 6 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | -12 |
| Tax % | 19% | 26% | 31% | 12% | 86% | 19% | 16% | 19% | -56% | 38% | 27% | 33% | |
| Net Profit | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -12 |
| EPS in Rs | 1.60 | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 2.27 | -78.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2022-2023 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | -100.00% | -100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Chemo Pharma Laboratories Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -4% |
| 3 Years: | -4% |
| TTM: | -1184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 64% |
| 3 Years: | 54% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: September 10, 2025, 3:20 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 3 | 4 | 4 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 | 12 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 0 |
| Other Assets | 4 | 4 | 4 | 11 | 10 | 10 | 11 | 11 | 9 | 9 | 9 | 13 |
| Total Assets | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 |
Below is a detailed analysis of the balance sheet data for Chemo Pharma Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
- For Reserves, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2024) to 12.00 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2024) to 13.00 Cr., marking an increase of 4.00 Cr..
- For Total Assets, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
Notably, the Reserves (12.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | 7% | 8% | 6% | 4% | 8% | 3% | 5% | 3% | 1% | 1% | 13% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 16 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -9.66 |
| Diluted EPS (Rs.) | -9.66 |
| Cash EPS (Rs.) | -9.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.49 |
| PBDIT / Share (Rs.) | -8.98 |
| PBIT / Share (Rs.) | -8.98 |
| PBT / Share (Rs.) | -8.98 |
| Net Profit / Share (Rs.) | -9.66 |
| NP After MI And SOA / Share (Rs.) | -9.66 |
| Return on Networth / Equity (%) | -39.44 |
| Return on Capital Employeed (%) | -35.51 |
| Return On Assets (%) | -37.44 |
| Current Ratio (X) | 28.82 |
| Quick Ratio (X) | 28.82 |
| Enterprise Value (Cr.) | 2.24 |
| EV / EBITDA (X) | -1.66 |
| Price / BV (X) | 0.72 |
| EarningsYield | -0.54 |
After reviewing the key financial ratios for Chemo Pharma Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 16, the value is -39.44. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 16, the value is -35.51. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 16, the value is -37.44. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 16, the value is 2.24. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 16, the value is -1.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 16, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 16, the value is -0.54. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemo Pharma Laboratories Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -35.51% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -39.44% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 28.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 5, Kumud Apartment CHS Ltd., Karnik Road, Chikan Ghar, Thane District Maharashtra 421301 | chemopharmalaboratorieslimited@gmail.com www.thechemopharmalaboratoriesltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ruchit Mehta | Managing Director & CEO |
| Mr. Utsav Trivedi | Executive Director & CFO |
| Ms. Shilpi Chopra | Non.Exe\Ind.Director |
| Ms. Simiran Ankleshwar Tripathi | Non.Exe\Ind.Director |
| Ms. Sarvagya Goel | Non.Exe\Ind.Director |
FAQ
What is the intrinsic value of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd's intrinsic value (as of 17 October 2025) is 37.21 which is 70.23% lower the current market price of 125.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 18.7 Cr. market cap, FY2025-2026 high/low of 154/63.0, reserves of ₹12 Cr, and liabilities of 13 Cr.
What is the Market Cap of Chemo Pharma Laboratories Ltd?
The Market Cap of Chemo Pharma Laboratories Ltd is 18.7 Cr..
What is the current Stock Price of Chemo Pharma Laboratories Ltd as on 17 October 2025?
The current stock price of Chemo Pharma Laboratories Ltd as on 17 October 2025 is 125.
What is the High / Low of Chemo Pharma Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemo Pharma Laboratories Ltd stocks is 154/63.0.
What is the Stock P/E of Chemo Pharma Laboratories Ltd?
The Stock P/E of Chemo Pharma Laboratories Ltd is .
What is the Book Value of Chemo Pharma Laboratories Ltd?
The Book Value of Chemo Pharma Laboratories Ltd is 87.6.
What is the Dividend Yield of Chemo Pharma Laboratories Ltd?
The Dividend Yield of Chemo Pharma Laboratories Ltd is 0.00 %.
What is the ROCE of Chemo Pharma Laboratories Ltd?
The ROCE of Chemo Pharma Laboratories Ltd is 5.17 %.
What is the ROE of Chemo Pharma Laboratories Ltd?
The ROE of Chemo Pharma Laboratories Ltd is 3.47 %.
What is the Face Value of Chemo Pharma Laboratories Ltd?
The Face Value of Chemo Pharma Laboratories Ltd is 10.0.